Conversely, inactivation of wild-type KRAS was expected to reduce tumor number and/or growth in the EGFR context, as EGFR signals via wild-type KRAS, and, as with NF1-deficiency, should not affect BRAF-driven tumors22. The gene discussed is BRAF; the disease is neoplasm.